NCT00516724 2025-04-11Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or PaclitaxelAstraZenecaPhase 1 Completed189 enrolled
NCT02658214 2020-08-20Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsAstraZenecaPhase 1 Completed32 enrolled